Effect of Denosumab or Alendronic Acid on the Progression of Aortic Stenosis: A Double-Blind Randomized Controlled Trial
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Background: Valvular calcification is central to the pathogenesis and progression of aortic stenosis, with preclinical and observational studies suggesting that bone turnover and osteoblastic differentiation of valvular interstitial cells are important contributory mechanisms. We aimed to establish whether inhibition of these pathways with denosumab or alendronic acid could reduce disease progression in aortic stenosis. Methods: In a single-center, parallel group, double-blind randomized controlled trial, patients >50 years of age with calcific aortic stenosis (peak aortic jet velocity >2.5 m/s) were randomized 2:1:2:1 to denosumab (60 mg every 6 months), placebo injection, alendronic acid (70 mg once weekly), or placebo capsule. Participants underwent serial assessments with Doppler echocardiography, computed tomography aortic valve calcium scoring, and 18 F-sodium fluoride positron emission tomography and computed tomography. The primary end point was the calculated 24-month change in aortic valve calcium score. Results: A total of 150 patients (mean age, 72±8 years; 21% women) with calcific aortic stenosis (peak aortic jet velocity, 3.36 m/s [2.93–3.82 m/s]; aortic valve calcium score, 1152 AU [655–2065 AU]) were randomized and received the allocated trial intervention: denosumab (n=49), alendronic acid (n=51), and placebo (injection n=25, capsule n=25; pooled for analysis). Serum C-terminal telopeptide, a measure of bone turnover, halved from baseline to 6 months with denosumab (0.23 [0.18–0.33 µg/L] to 0.11 µg/L [0.08–0.17 µg/L]) and alendronic acid (0.20 [0.14–0.28 µg/L] to 0.09 µg/L [0.08–0.13 µg/L]) but was unchanged with placebo (0.23 [0.17–0.30 µg/L] to 0.26 µg/L [0.16–0.31 µg/L]). There were no differences in 24-month change in aortic valve calcium score between denosumab and placebo (343 [198–804 AU] versus 354 AU [76–675 AU]; P=0.41) or alendronic acid and placebo (326 [138–813 AU] versus 354 AU [76–675 AU]; P =0.49). Similarly, there were no differences in change in peak aortic jet velocity or 18 F-sodium fluoride aortic valve uptake. Conclusions: Neither denosumab nor alendronic acid affected progression of aortic valve calcification in patients with calcific aortic stenosis. Alternative pathways and mechanisms need to be explored to identify disease-modifying therapies for the growing population of patients with this potentially fatal condition. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02132026.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantification of coronary artery calcium using ultrafast computed tomography
Agatston, A. S., Janowitz, W. R., Hildner, F. J., Zusmer, N. R., Viamonte, M., & Detrano, R. (1990) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(90)90282-t · Cited by 7,786
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000923 · Cited by 3,686
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483
Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
Rossebø, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, Y. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804602 · Cited by 1,644
Aortic Stenosis in the Elderly
Osnabrugge, R. L. J., Mylotte, D., Head, S. J., Van Mieghem, N. M., Nkomo, V. T., LeReun, C. M., Bogers, A. J. J. C., Piazza, N., & Kappetein, A. P. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.015 · Cited by 1,378
Otto, C. M., Burwash, I. G., Legget, M. E., Munt, B. I., Fujioka, M., Healy, N. L., Kraft, C. D., Miyake-Hull, C. Y., & Schwaegler, R. G. (1997) · Circulation · doi:10.1161/01.cir.95.9.2262 · Cited by 1,146
A Randomized Trial of Intensive Lipid-Lowering Therapy in Calcific Aortic Stenosis
Cowell, S. J., Newby, D. E., Prescott, R. J., Bloomfield, P., Reid, J., Northridge, D. B., & Boon, N. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043876 · Cited by 1,146
Self-citationRajamannan, N. M., Evans, F. J., Aikawa, E., Grande-Allen, K. J., Demer, L. L., Heistad, D. D., Simmons, C. A., Masters, K. S., Mathieu, P., O'Brien, K. D., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.006767 · Cited by 842
Chan, K. L., Teo, K., Dumesnil, J. G., Ni, A., & Tam, J. (2010) · Circulation · doi:10.1161/circulationaha.109.900027 · Cited by 815
Computed Tomography Aortic Valve Calcium Scoring in Patients With Aortic Stenosis
Pawade, T., Clavel, M.-A., Tribouilloy, C., Dreyfus, J., Mathieu, T., Tastet, L., Renard, C., Gun, M., Jenkins, W. S. A., Macron, L., et al. (2018) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.117.007146 · Cited by 397
Self-citation
Cited by
2025 ESC/EACTS Guidelines for the management of valvular heart disease
Praz, F., Borger, M. A., Lanz, J., Marin-Cuartas, M., Abreu, A., Adamo, M., Ajmone Marsan, N., Barili, F., Bonaros, N., Cosyns, B., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf194 · Cited by 1,072
Self-citationCalcific aortic valve disease: mechanisms, prevention and treatment
Moncla, L.-H. M., Briend, M., Bossé, Y., & Mathieu, P. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00845-7 · Cited by 306
Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy
Kraler, S., Blaser, M. C., Aikawa, E., Camici, G. G., & Lüscher, T. F. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab757 · Cited by 281
Calcific Aortic Stenosis: A Review
Otto, C. M., Newby, D. E., & Hillis, G. S. (2024) · JAMA · doi:10.1001/jama.2024.16477 · Cited by 97
Self-citationMulti-modality imaging in aortic stenosis: an EACVI clinical consensus document
Dweck, M. R., Loganath, K., Bing, R., Treibel, T. A., McCann, G. P., Newby, D. E., Leipsic, J., Fraccaro, C., Paolisso, P., Cosyns, B., et al. (2023) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jead153 · Cited by 79
Self-citationLipoprotein(a) and Calcific Aortic Valve Stenosis Progression: A Systematic Review and Meta-Analysis
Arsenault, B. J., Loganath, K., Girard, A., Botezatu, S., Zheng, K. H., Tzolos, E., Abdoun, K., Tastet, L., Capoulade, R., Côté, N., et al. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.1882 · Cited by 80
Self-citationCalcific aortic stenosis: omics-based target discovery and therapy development
Blaser, M. C., Bäck, M., Lüscher, T. F., & Aikawa, E. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehae829 · Cited by 45
Effect of evogliptin on the progression of aortic valvular calcification
Song, J.-K., Lee, S., Kim, Y.-J., Kim, H.-K., Ha, J.-W., Choi, E.-Y., Park, S.-W., Park, S.-J., Park, Y.-H., Park, J.-H., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.037 · Cited by 28
Lembo, M., Joshi, S. S., Geers, J., Bing, R., Carnevale, L., Pawade, T. A., Doris, M. K., Tzolos, E., Grodecki, K., Cadet, S., et al. (2024) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2024.06.007 · Cited by 29
Self-citation
Metadata
- Authors
- Pawade, T. A., Doris, M. K., Bing, R., White, A. C., Forsyth, L., Evans, E., Graham, C., Williams, M. C., van Beek, E. J. R., Fletcher, A., Adamson, P. D., Andrews, J. P. M., Cartlidge, T. R. G., Jenkins, W. S. A., Syed, M., Fujisawa, T., Lucatelli, C., Fraser, W., Ralston, S. H., Boon, N., Prendergast, B., Newby, D. E., & Dweck, M. R.
- Venue
- Circulation
- Published
- 2021-06-22
- Volume
- 143
- Issue
- 25
- Pages
- 2418-2427
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W3158108305
- Cited by
- 151
- References
- 17
- FWCI
- 14.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.